Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Date:2/29/2008

cally indicated, oral ABILIFY in a range of 10 mg/day to 30 mg/day should replace ABILIFY Injection as soon as possible. The safety of doses of ABILIFY Oral or ABILIFY Injection above 30 mg/day has not been evaluated in clinical trials.

IMPORTANT SAFETY INFORMATION and INDICATIONS for ABILIFY

INDICATIONS:

-- ABILIFY is indicated for acute and maintenance treatment of adults

with manic or mixed episodes associated with Bipolar I Disorder with

or without psychotic features

-- ABILIFY is indicated for acute treatment of pediatric patients (10 to

17 years old) with manic or mixed episodes associated with Bipolar I

Disorder with or without psychotic features

-- ABILIFY Injection is indicated for the treatment of adults with

agitation associated with Bipolar I Disorder, manic or mixed.

IMPORTANT SAFETY INFORMATION:

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death compared to placebo (4.5% vs 2.6%, respectively). ABILIFY is not approved for the treatment of patients with dementia-related psychosis (see Boxed WARNING).

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of adjunctive ABILIFY or another antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increased risk of suicidality in adults beyond age 24. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusu
'/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
2. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
5. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
6. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
7. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
10. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- Seres Health, a clinical-stage therapeutics company developing novel treatments ... that it has been named by FierceBiotech ... it as one of the most promising private biotechnology ... great deal of ain,t-it-cool science in microbiomics, Seres Health ... therapeutic development," says Damian Garde , editor of ...
(Date:9/22/2014)... , Sept. 22, 2014 Thoratec Corporation ... device-based mechanical circulatory support therapies to save, support and ... Grossman has been appointed President and Chief Executive ... , who has stepped down from his executive and ... the company through the first quarter of 2016.  ...
(Date:9/22/2014)... Sept. 22, 2014  Prostate cancer is the second ... is easily treated when caught early - the problem ... why the Prostate Conditions Education Council (PCEC), ... a leader in prostate cancer screening –  is sponsoring ... (PCAW) from September 22-27.  Committed to ...
Breaking Medicine Technology:Seres Health Named a "Fierce 15" Biotech Company for 2014 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3
... Today, Roche honored 11 outstanding Ph.D. students and two professors with ... the field of organic chemistry. The winners are participating in Roche,s annual ... first hand knowledge on the important role organic chemistry plays in pharmaceutical ... "This symposium ...
... PARIS , June 3, 2010 ... organisation bringing together global,forces in personalised medicine, has today ... entrepreneur in personalised healthcare, as Executive,Director and board member. ... and, together with the board of directors, for building,its ...
Cached Medicine Technology:Roche Symposium Showcases Accomplishments of Next Generation of Chemists 2Roche Symposium Showcases Accomplishments of Next Generation of Chemists 3Roche Symposium Showcases Accomplishments of Next Generation of Chemists 4Roche Symposium Showcases Accomplishments of Next Generation of Chemists 5EPEMED, the European Personalised Medicine Association, Appoints Executive Director 2EPEMED, the European Personalised Medicine Association, Appoints Executive Director 3
(Date:9/22/2014)... 22, 2014 Quincy Bioscience, one ... States, promotes National Self-Improvement Month this ... individuals should have access to self-improvement resources, especially ... The demand for products that preserve health is ... before. For over six years, Quincy Bioscience has ...
(Date:9/22/2014)... Scans of young children,s brains might help predict ... potentially allow doctors to identify those with dyslexia ... suggests. "Early identification and interventions are extremely ... most neurodevelopmental disorders," the study,s senior author, Dr. ... adolescent psychiatry at University of California, San Francisco ...
(Date:9/22/2014)... In a continued effort to support the ... launching an awareness campaign inspired by the ice bucket ... to raise awareness and funds for the cause. , ... the air and trying to catch it while blindfolded. ... nominee does not complete the challenge within 24 hours ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 The struggles ... English proficiency (LEP) patients has been well-documented—reportedly, language barriers ... repeat visits to the emergency room and an increased ... , At Sanford Health, the largest medical facility ... a rising LEP population necessitated the need for ...
(Date:9/22/2014)... Tenn. (PRWEB) September 22, 2014 ... contact center and customer service solutions. , WHAT: ... is focused on customer care for the connected ... landscapes continue to offer new challenges and opportunities ... to helping attendees identify best practices, network and ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 3Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2
... is associated with an increased risk of heart failure and ... concludes a study published on bmj.com today. ... continued use of rosiglitazone for most patients. Rosiglitazone and ... are widely used for the treatment of type 2 diabetes. ...
... year, 500,000 project to co-ordinate European and international ... treat malaria. The CRIMALDDI project (Coordination, Rationalisation ... Initiatives) is being led by the Liverpool School ... players in the antimalarial drug discovery fields including ...
... Having 45 million doses by Oct. 15 will still be ... Health experts do not believe that the delay in receiving ... protect Americans against the newly circulating virus. , But having ... than the originally anticipated 120 million doses, does throw a ...
... , MONROVIA, Calif., Aug. 20 STAAR Surgical Company ... minimally invasive ophthalmic products, today reported on the status of its application ... , , As anticipated, the Ministry of Health, Labour ... in Japan, at which time the STAAR Visian ICL products were considered ...
... ... and innovative charitable program that provides free hair restoration services to children suffering from ... ... , the world,s first online social network community dedicated to all-things hair loss has ...
... ... Sparsense, the developer of a novel image and signal processing ... firm. The exclusive partnership will allow the development of various custom ... applications. The new technology can be applied to MRI, MR video ...
Cached Medicine News:Health News:Diabetes drug linked to increased risk of heart failure 2Health News:LSTM to lead EU project to coordinate antimalarial drug research 2Health News:Swine Flu Vaccine Delay Manageable, Experts Say 2Health News:Swine Flu Vaccine Delay Manageable, Experts Say 3Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 2Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 3Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 4Health News:Hair Loss Website Launches Program for Children 2Health News:Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 2Health News:Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: